With three million people dying of tuberculosis annually, the World Health Organization has declared tuberculosis a global emergency [1] . On the other hand, the same institution has estimated that two billion individuals have been infected with the etiologic agent of this disease, Mycobacterium tuberculosis, the vast majority of whom will harbor the pathogen without ever developing the disease. Thus, it appears that M. tuberculosis lives in balanced coexistence with the human host in most instances and only rarely becomes detrimental. The immune system must therefore be extremely efficacious in controlling M. tuberculosis and is only overwhelmed after losing its full activity.
M. tuberculosis is an intracellular bacterial pathogen that preferentially resides within resting macrophages, bacteria-engulfing cells of the immune system; once the macrophages have been activated adequately, they become the major effector cells in the immune response against this pathogen. In mice, the cytokine interferon γ (IFN-γ) produced by CD4 + T helper cells has been shown to stimulate antimycobacterial activities in macrophages which thus become endowed with the capacity to control their intracellular predators. The major effector molecules of activated macrophages in mice are the reactive nitrogen intermediates, which kill bacteria by causing damage to proteins and DNA. Although evidence to support a protective role of IFN-γ and reactive nitrogen intermediates in human tuberculosis is increasing, these factors appear to be less potent in man than in mice. Therefore, the question arises as to whether other immune mechanisms are required for efficient control of M. tuberculosis because this pathogen is found in the two billion individuals that are infected, yet are free of active disease.
One candidate mechanism of protection could be afforded by the second main function of T cells, namely cytotoxic activity, typically exhibited by CD8 + T cells. These CD8 + cytotoxic T lymphocytes (CTLs) are central to the control of viral infections. By lysing virus-infected host cells, CTLs also reduce viral synthesis, thus promoting virus elimination. At the same time, however, destruction of host cells bears a certain risk for the host and this gains increasing relevance the more valuable the affected cells are or the more difficult it is to replace them. Two recent publications from Stenger et al. [2, 3] emphasize a role for CTLs in the control of human tuberculosis and have revealed insights into the underlying molecular mechanism.
Principally, CTLs can kill target cells via two major pathways. First, they express the death-inducing molecule Fas ligand (FasL) on their cell surface and this molecule, upon interaction with its receptor Fas on target cells, activates a suicide pathway in the target cells. This killing mechanism is not unique to CTLs; rather, it occurs frequently during apoptosis, a form of programmed cell death. Second, CTLs have unique cytoplasmic granules containing various effector molecules with cytolytic activity, such as perforin and granzymes. Once CTLs have come into close contact with their target cells, they exocytose their granular content. Perforin is released and forms pores in the target cell membrane, causing cellular swelling, rupture, and eventually death. The perforin pores also open a port for the entry of granzymes that are released from the granules and subsequently induce apoptosis in the target cells. In this way, these two killer mechanisms synergize to achieve target cell destruction in a most efficient way.
In mice, CTLs that could lyse target cells infected with intracellular bacteria, such as M. tuberculosis, were described a decade ago [4] . It was also observed at that time that the growth of M. tuberculosis was inhibited concomitantly with target cell killing. Even prior to this, direct killing of bacterial and fungal pathogens by natural killer (NK) cells -lymphoid cells with cytolytic activity -had been described [4] . It was thus postulated that CTLs, like cytokine-producing CD4 + T helper cells, are involved in the immune response to microbial infections, including tuberculosis ( Figure 1 ) [4] .
Although the possibility that target cell lysis could contribute to pathogenesis had been considered, lysis was assumed to have a more protective role: either CTLs could directly affect intracellular pathogens or these lymphocytes could liberate the pathogens from protective intracellular niches, thus promoting their killing by more proficient phagocytes (Figure 1 ). Experiments using perforin-deficient mice have verified a protective role of CTLs in vivo. These mice were hampered in their capacity to control infection of the model intracellular pathogen Listeria monocytogenes [5] . To the contrary, it was claimed that the perforin-deficient mice were not impaired in their capacity to control M. tuberculosis infection [6, 7] . The latter findings, however, may need to be revisited because the recent paper by Stenger et al. [2] mentions unpublished data from the same groups indicating exacerbation of tuberculosis in perforin-deficient mice at late stages of disease.
The above studies were all performed in mice and, until recently, the contribution of CD8 + T cells and of target cell lysis to defence against tuberculosis in man remained largely obscure. Firstly, mycobacteria-reactive CD8 + T cells have been identified in tuberculosis patients [8] . Now, Stenger et al. [3] not only show that human mycobacteriareactive CD8 + T cells express CTL activity, but also that target cell lysis is accompanied by growth inhibition of intracellular M. tuberculosis. Interestingly, CTLs that were reactive to M. tuberculosis were not of the conventional CD8 + T lymphocyte type that recognizes antigenic peptides bound to major histocompatibility complex (MHC) class I molecules. Rather, they were CD8 + T cells that recognized mycobacterial glycolipids presented by CD1 molecules, which are related to MHC molecules. The glycolipids are abundant components of the mycobacterial cell wall, suggesting that CD1-restricted glycolipid-specific T cells evolved to combat these major bacterial pathogens. In the study by Stenger et al. [3] , all of the CD8 + T cells that inhibited M. tuberculosis growth contained the granular killer machinery, but lacked cell-surface expression of FasL. In contrast, CTLs that utilized FasL-Fas interactions as their main mechanism of killing apparently did not affect the growth of M. tuberculosis in target macrophages [3] .
In their more recent study, Stenger et al. [2] identified the antimycobacterial effector molecule of CTLs as granulysin, a previously identified component of cytotoxic granules in CTLs and NK cells [2] . This molecule expresses potent killer activity against many Gram-positive and Gram-negative bacteria and fungi, reducing their numbers by several orders of magnitude in vitro. It also kills and inhibits the growth of M. tuberculosis, though less potently than its effects on the other bacteria and fungi. Mycobacteria are extremely slow-growing with a doubling time of 8-12 hours in vitro and they are remarkably resistant to various chemicals and disinfectants, and numerous conventional antibiotics. To a large extent this is due to the waxy, glycolipid-rich cell wall that probably also provides partial resistance against granulysin. Although M. tuberculosis organisms that resided in their natural habitat -the macrophage -were fully protected against granulysin, addition of perforin overcame this obstacle. Presumably the pores formed by perforin in the macrophage membrane promoted access of granulysin to the intracellular predators (Figure 1) . Together, these findings clearly point to granulysin and the granular killer machinery as the key weapon of CTLs in their fight against M. tuberculosis and argue against the participation of apoptosis.
In contrast, a recent study advocated apoptosis as the relevant mechanism of M. tuberculosis growth inhibition and killing by CTLs [9] . In these experiments, induction of apoptosis in macrophages infected with M. tuberculosis inhibited the growth of the pathogens to the same degree as observed in the studies by Stenger et al. [3] . It is most likely that there are a range of mechanisms of mycobacterial inhibition by CTLs. For example, it was shown previously that exogenous ATP causes death both of macrophages and of intracellular M. bovis Bacille Camille Guerin (BCG) [10] , a microbe that can be used as a model pathogen in such studies as well as being more commonly used as an anti-tuberculosis vaccine. Mycobacterial growth inhibition is induced by binding of exogenous ATP to specific cell surface receptors on macrophages, and ATP is released by CTLs upon target cell interaction. Hence, it appears that, depending on the conditions, various CTL activities have the potential to inhibit the growth of intracellular M. tuberculosis. Time will reveal whether all of these mechanisms are equally important, whether a hierarchy exists, or whether the mechanisms synergize to achieve maximum effects.
M. tuberculosis, as well as many other bacterial pathogens, poses increasing problems globally due to the emergence of multidrug-resistant strains against which classical chemotherapies are no longer effective [1] . The need for conceptually novel anti-infective agents is therefore obvious. Antibiotics are generally developed from substances that are produced by microbes to provide themselves with a survival advantage over other microorganisms. In contrast, granulysin represents an effector molecule of the mammalian immune system. It would be rewarding if we could learn from our own defence strategies how to design new anti-infective agents for the fight against major scourges such as tuberculosis.
